Wide Ranks

AGIO

Agios Pharmaceuticals, Inc.

58.66

Top Statistics
Market Cap 3 B Forward PE -10.65 Revenue Growth 21.20 %
Current Ratio 8.99 Trailing PE 5.03 Earnings Growth 0.00 %
Profit Margins 2051.38 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -5.98 Enterprise / Revenue 73.06 Price To Sales Trailing12 Months 101.77
Profitability
Profit Margins 2051.38 % Operating Margins -1146.93 %
Balance Sheet
Total Cash 1 B Total Cash Per Share 17.62 Total Debt 60 M
Total Debt To Equity 3.74 Current Ratio 8.99 Book Value Per Share 28.53
All Measures
Short Ratio 665.00 % Message Board Id finmb_46539787 Shares Short Prior Month 4 M
Return On Equity 0.5365 City Cambridge Uuid 52f076ec-0de6-382e-b01b-3ddfa165dcb4
Previous Close 59.10 First Trade Date Epoch Utc 1 B Book Value 28.53
Beta 0.7510 Total Debt 60 M Volume 436256
Price To Book 2.06 Fifty Two Week Low 20.96 Total Cash Per Share 17.62
Total Revenue 32 M Shares Short Previous Month Date 1 B Target Median Price 55.50
Max Age 86400 Recommendation Mean 2.00 Sand P52 Week Change 0.3133
Operating Margins -1146.93 % Target Mean Price 53.88 Net Income To Common 674 M
Short Percent Of Float 0.0809 Implied Shares Outstanding 57 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 556300 Average Volume10days 556300
Total Cash 1 B Next Fiscal Year End 1 B Revenue Per Share 0.5820
Held Percent Insiders 0.0151 Trailing PE 5.03 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 59.10 Target Low Price 46.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 48.19 Open 59.29
Free Cashflow -157062624 State MA Dividend Yield 0.00 %
Return On Assets -0.1817 Time Zone Short Name EST Trailing Eps 11.66
Day Low 57.98 Address1 88 Sidney Street Shares Outstanding 57 M
Price Hint 2 Target High Price 57.00 Website https://www.agios.com
52 Week Change 1.64 Average Volume 568853 Forward Eps -6.08
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 843.80 %
Is_sp_500 False Regular Market Day High 59.62 Profit Margins 2051.38 %
Debt To Equity 3.74 Fifty Two Week High 62.58 Day High 59.62
Shares Short 4 M Regular Market Open 59.29 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 73.06 Revenue Growth 21.20 %
Shares Percent Shares Out 0.0798 Operating Cashflow -329161984 Currency USD
Time Zone Full Name America/New_York Market Cap 3 B Is_nasdaq_100 False
Zip 02139 Quote Type EQUITY Industry Biotechnology
Long Name Agios Pharmaceuticals, Inc. Regular Market Day Low 57.98 Held Percent Institutions 1.07
Current Price 58.66 Enterprise To Ebitda -5.98 Financial Currency USD
Current Ratio 8.99 Industry Disp Biotechnology Number Of Analyst Opinions 8
Country United States Float Shares 50 M Two Hundred Day Average 40.77
Enterprise Value 2 B Price To Sales Trailing12 Months 101.77 Forward PE -10.65
Regular Market Volume 436256 Ebitda -401288000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.

Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.

Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder.

Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.